These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 18285836)

  • 1. Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach.
    Tischkowitz M; Hamel N; Carvalho MA; Birrane G; Soni A; van Beers EH; Joosse SA; Wong N; Novak D; Quenneville LA; Grist SA; ; Nederlof PM; Goldgar DE; Tavtigian SV; Monteiro AN; Ladias JA; Foulkes WD
    Eur J Hum Genet; 2008 Jul; 16(7):820-32. PubMed ID: 18285836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis for cell cycle checkpoint control by the BRCA1-CtIP complex.
    Varma AK; Brown RS; Birrane G; Ladias JA
    Biochemistry; 2005 Aug; 44(33):10941-6. PubMed ID: 16101277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphopeptide binding specificities of BRCA1 COOH-terminal (BRCT) domains.
    Rodriguez M; Yu X; Chen J; Songyang Z
    J Biol Chem; 2003 Dec; 278(52):52914-8. PubMed ID: 14578343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis of BACH1 phosphopeptide recognition by BRCA1 tandem BRCT domains.
    Botuyan MV; Nominé Y; Yu X; Juranic N; Macura S; Chen J; Mer G
    Structure; 2004 Jul; 12(7):1137-46. PubMed ID: 15242590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining Homologous Recombination and Phosphopeptide-binding Data to Predict the Impact of
    Petitalot A; Dardillac E; Jacquet E; Nhiri N; Guirouilh-Barbat J; Julien P; Bouazzaoui I; Bonte D; Feunteun J; Schnell JA; Lafitte P; Aude JC; Noguès C; Rouleau E; Lidereau R; Lopez BS; Zinn-Justin S; Caputo SM;
    Mol Cancer Res; 2019 Jan; 17(1):54-69. PubMed ID: 30257991
    [No Abstract]   [Full Text] [Related]  

  • 6. Structure of the BRCT repeats of BRCA1 bound to a BACH1 phosphopeptide: implications for signaling.
    Shiozaki EN; Gu L; Yan N; Shi Y
    Mol Cell; 2004 May; 14(3):405-12. PubMed ID: 15125843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.
    Lee MS; Green R; Marsillac SM; Coquelle N; Williams RS; Yeung T; Foo D; Hau DD; Hui B; Monteiro AN; Glover JN
    Cancer Res; 2010 Jun; 70(12):4880-90. PubMed ID: 20516115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCT domains: phosphopeptide binding and signaling modules.
    Rodriguez MC; Songyang Z
    Front Biosci; 2008 May; 13():5905-15. PubMed ID: 18508631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of cancer-linked BRCA1-BRCT missense variants and their interaction with phosphoprotein targets.
    Drikos I; Nounesis G; Vorgias CE
    Proteins; 2009 Nov; 77(2):464-76. PubMed ID: 19452558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1.
    Williams RS; Lee MS; Hau DD; Glover JN
    Nat Struct Mol Biol; 2004 Jun; 11(6):519-25. PubMed ID: 15133503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell signaling. The BRCT domain: signaling with friends?
    Caldecott KW
    Science; 2003 Oct; 302(5645):579-80. PubMed ID: 14576410
    [No Abstract]   [Full Text] [Related]  

  • 12. Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer.
    Clapperton JA; Manke IA; Lowery DM; Ho T; Haire LF; Yaffe MB; Smerdon SJ
    Nat Struct Mol Biol; 2004 Jun; 11(6):512-8. PubMed ID: 15133502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCT repeats as phosphopeptide-binding modules involved in protein targeting.
    Manke IA; Lowery DM; Nguyen A; Yaffe MB
    Science; 2003 Oct; 302(5645):636-9. PubMed ID: 14576432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis for the BRCA1 BRCT interaction with the proteins ATRIP and BAAT1.
    Liu X; Ladias JA
    Biochemistry; 2013 Oct; 52(43):7618-27. PubMed ID: 24073851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation.
    Fernandes VC; Golubeva VA; Di Pietro G; Shields C; Amankwah K; Nepomuceno TC; de Gregoriis G; Abreu RBV; Harro C; Gomes TT; Silva RF; Suarez-Kurtz G; Couch FJ; Iversen ES; Monteiro ANA; Carvalho MA
    J Biol Chem; 2019 Apr; 294(15):5980-5992. PubMed ID: 30765603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of BRCA1 BRCT domain missense substitutions on phosphopeptide recognition.
    Coquelle N; Green R; Glover JN
    Biochemistry; 2011 May; 50(21):4579-89. PubMed ID: 21473589
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Drikos I; Boutou E; Kastritis PL; Vorgias CE
    Anticancer Res; 2021 Jun; 41(6):2953-2962. PubMed ID: 34083286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of a novel mutation in exon 20 of the BRCA1 gene.
    Chakraborty A; Katarkar A; Chaudhuri K; Mukhopadhyay A; Basak J
    Cell Mol Biol Lett; 2013 Dec; 18(4):631-8. PubMed ID: 24297685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.
    Sato K; Koyasu M; Nomura S; Sato Y; Kita M; Ashihara Y; Adachi Y; Ohno S; Iwase T; Kitagawa D; Nakashima E; Yoshida R; Miki Y; Arai M
    Cancer Sci; 2017 Nov; 108(11):2287-2294. PubMed ID: 28796317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in the BRCT binding site of BRCA1 result in hyper-recombination.
    Dever SM; Golding SE; Rosenberg E; Adams BR; Idowu MO; Quillin JM; Valerie N; Xu B; Povirk LF; Valerie K
    Aging (Albany NY); 2011 May; 3(5):515-32. PubMed ID: 21666281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.